NCI Division of Cancer Treatment and Diagnosis

Welcome to the NCI Division of Cancer Treatment and Diagnosis (DCTD) LinkedIn page! Led by DCTD Director James H. Doroshow, M.D., our mission is to support the development of novel diagnostic and therapeutic approaches for cancer by expediting the initial and subsequent large-scale testing of new agents, biomarkers, imaging tests, and other diagnostic and therapeutic interven­tions (radiation, surgery, immunotherapy) in patients with cancer. https://dctd.cancer.gov

On November 4th at 1:00 pm ET, Dr. Vladimir Ponomarev will discuss advances in imaging in cancer cell therapies at the National Cancer Institute (NCI) Imaging Community Webinar organized by DCTD’s Cancer Imaging Program. Join here: https://lnkd.in/dJtu_5K5

DCTD invites comparative oncology investigators and veterinary oncologists working with pet dogs that develop spontaneous cancers to contribute annotated data to the National Cancer Institute (NCI) Integrated Canine Data Commons (ICDC): https://lnkd.in/euqG9S3j The ICDC is a cloud-based data repository node within the Cancer Research Data Commons (https://lnkd.in/g6weC9br) that permits scientists to explore, analyze, and understand the biological relationships between human and canine cancers. The scientific community can use the ICDC free of charge. The ICDC seeks these types of annotated data: - Genomic, transcriptomic, epigenetic, and proteomic data on canine tumors - Longitudinal data on dogs followed pre-diagnosis, at diagnosis, on therapy, and at recurrence - Information about canine clinical specimens that could be shared with other researchers in the field, as we will be expanding the ICDC to include a repository of specimen data More information on how to submit data here: https://lnkd.in/eaqgZCMQ. 

DCTD’s Cancer Imaging Program is seeking a SUPERVISORY PHYSICIAN (ASSOCIATE DIRECTOR) to plan, conduct, coordinate and evaluate a broad array of national and international laboratory and clinical research programs designed to identify and develop new imaging approaches to the diagnosis and treatment of cancer. This is an exploratory ad to gauge interest. For more information, email your resume to NCIDCTDvacancyinquiry@mail.nih.gov and visit our careers page under “Physicians”: https://lnkd.in/ddaqMeG6

National Cancer Institute (NCI)'s Biorepositories and Biospecimen Research Branch (BBRB) invites you to our Biobanking for Precision Medicine Seminar Series with Dr. Karol Bomsztyk on October 30, 2024 from 1:00 PM to 2:30 PM EST. Registration prior to the seminar is required: https://lnkd.in/gdxejyDH Dr. Bomsztyk is a Professor of Medicine and Allergy and Infectious Diseases at the University of Washington. His research focuses on fluid and electrolyte disorders, epigenetics-based translational research to develop diagnostic tools, and potential treatment of kidney disease and other conditions. He obtained his MD from University of Rochester and is a board-certified internist and nephrologist. The Biobanking for Precision Medicine Seminar Series is intended to be forward-looking with a focus on improving awareness of best practices for collection of biospecimens and associated data as well as expanding research participation through biobanking. This year’s theme is “Biospecimen Science.” For more information, contact Dr. Veena Gopalakrishnan (veena.gopalakrishnan@nih.gov).

DCTD’s Developmental Therapeutics Program is seeking a PHARMACOLOGIST to coordinate and evaluate safety testing of investigational cancer therapies, and to evaluate/develop research protocols and pharmacokinetic study design initiatives. This is an exploratory ad to gauge interest. For more information, contact Dr. Elizabeth R. Glaze at glazee@mail.nih.gov and visit our careers page under “Scientific Positions”: https://lnkd.in/eiv9YPtQ

PRESS RELEASE: NCI has launched a precision medicine clinical trial to test new treatment combinations for some people with aggressive cancers of the blood and bone marrow, including acute myeloid leukemia and myelodysplastic syndromes. The proof-of-concept trial aims to accelerate the discovery of more tailored treatments for people with these cancers. https://go.nih.gov/ioneQ6q Media Description: Human cells with acute myelocytic leukemia (AML) in the pericardial fluid, shown with an esterase stain at 400x.

National Cancer Institute (NCI) DCTD staff members are part of this exciting collaboration 👇

National Cancer Institute (NCI) is convening a workshop virtually on January 28 and 29, 2025 on “In Vivo Engineering of Immune Cells (IVEIC) for Cancer Immunotherapy.” The workshop aims to spur discussion of the IVEIC approach, which reprograms specific immune cells inside the body, and foster collaboration among investigators from multidisciplinary fields of immuno-oncology, gene and cell engineering, and nanomaterials. Sessions will include discussions of: - Viral and synthetic-based gene delivery to generate CAR T cells in situ  - Precision genome editing technologies for immune cell reprogramming - In vivo cell engineering beyond CAR T cells - Clinical perspectives of the IVEIC approach The IVEIC workshop intends to inform and educate attendees of the emerging field of in vivo immune cell engineering for cellular immunotherapies and provide a context for comparison with the current ex vivo approaches. Registration and more information: https://lnkd.in/eEHJ2R-F

Robust preclinical evidence through standardized assays that simulate clinical scenarios and analyze molecular interactions is needed while developing drug-radiation combinations. Recognizing this, DCTD staff authored a publication in Lancet Oncology on approaches to enhancing outcomes of drug-radiation combinations to enhance efficacy and decrease toxicity. The paper discusses the importance of translating preclinical data effectively, focusing on assays for tumor regression, growth delay, and organ toxicity. It also highlights emerging areas in preclinical studies with drug radiation combinations that could foster innovation without hindering progress. More information here: https://lnkd.in/dsAx8xfb